CVRx Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.4%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$65.3Mnext fiscal year
FY EPS (est.)
-$1.96next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. Active Implanting Centers Quarterly257.0
U.S. Sales Territories Quarterly56.0
Medicare Advantage 30-Day Prior Authorization Approval Rate Monthly5,000.0%
Watch Items
- BENEFIT-HF Clinical Trial EnrollmentTrigger: Slower than expected site activation or patient recruitment across the planned 150 centersAction: Re-evaluate clinical operations support, increase investigator engagement, or adjust trial timeline expectations
- Salesforce Restructuring and Territory Manager ProductivityTrigger: High turnover or prolonged ramp-up times for newly hired territory managersAction: Enhance sales training programs, adjust compensation structures, or refine the regional recruitment strategy
- Medicare Advantage Prior Authorization PredictabilityTrigger: A decline in the 30-day approval rate below the early 2026 level of 50%Action: Deploy the in-house market access team to provide additional administrative support and appeal assistance to implanting centers
Research as of 20 Jun 2026